Free Trial

Renovaro (RENB) Competitors

Renovaro logo
$0.23 -0.01 (-2.55%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RENB vs. CCCC, CRBU, BTMD, ELDN, LYEL, CRDF, BIOA, CTMX, ACOG, and SLS

Should you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include C4 Therapeutics (CCCC), Caribou Biosciences (CRBU), biote (BTMD), Eledon Pharmaceuticals (ELDN), Lyell Immunopharma (LYEL), Cardiff Oncology (CRDF), BioAge Labs (BIOA), CytomX Therapeutics (CTMX), Alpha Cognition (ACOG), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

Renovaro vs. Its Competitors

C4 Therapeutics (NASDAQ:CCCC) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

C4 Therapeutics has a beta of 2.97, meaning that its stock price is 197% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

C4 Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 173.50%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe C4 Therapeutics is more favorable than Renovaro.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C4 Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Renovaro
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Renovaro has a net margin of 0.00% compared to C4 Therapeutics' net margin of -325.88%. C4 Therapeutics' return on equity of -53.91% beat Renovaro's return on equity.

Company Net Margins Return on Equity Return on Assets
C4 Therapeutics-325.88% -53.91% -33.26%
Renovaro N/A -60.38%-47.04%

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Comparatively, 0.5% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Renovaro has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4 Therapeutics$35.58M5.85-$105.32M-$1.58-1.85
RenovaroN/AN/A-$88.43M-$0.77-0.30

In the previous week, C4 Therapeutics had 2 more articles in the media than Renovaro. MarketBeat recorded 5 mentions for C4 Therapeutics and 3 mentions for Renovaro. Renovaro's average media sentiment score of 0.96 beat C4 Therapeutics' score of -0.03 indicating that Renovaro is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
C4 Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Renovaro
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

C4 Therapeutics beats Renovaro on 10 of the 15 factors compared between the two stocks.

Get Renovaro News Delivered to You Automatically

Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RENB vs. The Competition

MetricRenovaroMED IndustryMedical SectorNASDAQ Exchange
Market Cap$40.10M$3.13B$5.71B$9.79B
Dividend YieldN/A2.21%3.77%4.10%
P/E Ratio-0.3020.9230.9125.28
Price / SalesN/A232.70404.2188.50
Price / CashN/A41.5625.2228.45
Price / Book0.269.779.536.01
Net Income-$88.43M-$54.74M$3.26B$265.34M
7 Day Performance-2.14%8.37%4.66%2.89%
1 Month Performance-26.48%7.94%5.35%1.61%
1 Year Performance-65.65%18.27%32.14%25.61%

Renovaro Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RENB
Renovaro
1.7123 of 5 stars
$0.23
-2.6%
N/A-64.8%$40.10MN/A-0.3020Short Interest ↓
CCCC
C4 Therapeutics
1.7953 of 5 stars
$2.29
-5.6%
$8.00
+250.1%
-57.9%$162.62M$35.58M-1.45150
CRBU
Caribou Biosciences
3.3002 of 5 stars
$1.75
+2.0%
$6.67
+282.0%
-5.3%$162.29M$9.99M-1.08100News Coverage
Earnings Report
Analyst Downgrade
Analyst Revision
BTMD
biote
2.5043 of 5 stars
$2.97
+5.1%
$6.00
+102.4%
-49.6%$162.22M$197.19M3.29194
ELDN
Eledon Pharmaceuticals
1.8719 of 5 stars
$2.69
-0.7%
$10.00
+271.7%
-3.7%$161.08MN/A-1.2810Earnings Report
Short Interest ↑
LYEL
Lyell Immunopharma
3.2969 of 5 stars
$10.27
-2.9%
$15.00
+46.1%
-56.6%$160.17M$60K-0.41270Earnings Report
Analyst Downgrade
CRDF
Cardiff Oncology
1.9535 of 5 stars
$2.40
+2.8%
$10.10
+321.7%
+2.1%$159.34M$680K-2.7520
BIOA
BioAge Labs
N/A$4.40
+1.4%
N/AN/A$157.74MN/A0.00N/A
CTMX
CytomX Therapeutics
3.9442 of 5 stars
$1.95
-15.8%
$5.75
+195.6%
+59.2%$156.81M$138.10M3.47170Gap Up
ACOG
Alpha Cognition
1.6986 of 5 stars
$9.77
-2.2%
$20.00
+104.7%
N/A$156.52MN/A-8.14N/AEarnings Report
Analyst Downgrade
SLS
SELLAS Life Sciences Group
2.7079 of 5 stars
$1.54
-0.3%
$7.00
+356.0%
+23.5%$153.16M$1M-4.0410Earnings Report
Options Volume

Related Companies and Tools


This page (NASDAQ:RENB) was last updated on 8/18/2025 by MarketBeat.com Staff
From Our Partners